FEATURES


Viewpoints

Legal Challenges Begin for Biosimilar Agents

Legal Challenges Begin for Biosimilar Agents

As key biologics near the end of their patent-protection periods, industry is preparing for legal battles over biosimilar versions.

Chemoradiation Therapy May Benefit Some Patients with Resectable Gastric Cancer

Chemoradiation Therapy May Benefit Some Patients with Resectable Gastric Cancer

Recent analysis indicated an increase in survival in gastric cancer patients who received chemoradiation compared with chemotherapy alone.

Feature Articles

Incidence and prognostic impact of high-risk HPV tumor infection in cervical esophageal carcinoma

Incidence and prognostic impact of high-risk HPV tumor infection in cervical esophageal carcinoma

[Journal of Gastrointestinal Oncology] This study examines outcomes of CEC patients treated with CRT and the incidence and potential role of HPV tumor infection in CEC lesions.

Survival Improved With Evolving Treatment Approaches for Metastatic Melanoma

Survival Improved With Evolving Treatment Approaches for Metastatic Melanoma

Update on available treatment options and potential future developments for metastatic melanoma with and without BRAF mutations.

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics

[Lung Cancer: Targets and Therapy] The appropriate role of EGFR mutation analysis in the treatment of patients with NSCLC is constantly evolving; EGFR mutation testing can help simplify the drug discovery process and individualize cancer therapy.

Slideshows

ZYDELIG® (idelalisib) for Relapsed Follicular B-cell Non-Hodgkin Lymphoma (FL)

ZYDELIG® (idelalisib) for Relapsed Follicular B-cell Non-Hodgkin Lymphoma (FL)

This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed follicular non-Hodgkin lymphoma (FL).

Table of Contents

Slide 3: Indication, Dosage, ...

ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia

ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia

This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed chronic lymphoma.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide ...

From the Advisory Board

MM-398: A Potential New Option for Metastatic Pancreatic Cancer?

MM-398: A Potential New Option for Metastatic Pancreatic Cancer?

CTA Board Member Steven Cohen, MD, discusses exciting advances regarding treatment options for metastatic pancreatic cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs